Medtronic (MDT) Momentum at All-Time-High Levels
Post# of 99
Posted On: 02/21/2015 12:44:21 AM
The price of Medtronic plc (MDT) stock reached a new all-time high in intraday trading on Friday's market activity.
The company announced five-year results from the pivotal SANTE (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy) trial, the largest clinical study of deep brain stimulation (DBS) therapy for epilepsy in adults with treatment-resistant (refractory) epilepsy characterized by partial-onset seizures.
MDT said that its DBS Therapy for Epilepsy was associated with a sustained and statistically significant reduction in seizure frequency from baseline that continued to improve over time, and the results also show sustained safety, intervals of seizure freedom, improvements in quality of life and reduction in seizure severity
MDT's DBS Therapy for Epilepsy uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver electrical stimulation to a target in the brain called the anterior nucleus of the thalamus, which has strong connections to other parts of the brain where seizures begin.
Furthermore, the U.S. Food and Drug Administration (FDA) has approved the VenaSeal closure system (VenaSeal system) to permanently treat varicose veins of the legs by sealing the affected superficial veins using an adhesive agent. The device is manufactured by Covidien LLC, whose acquisition MDT completed last month for $49.9 billion.
MDT's VenaSeal system permanently treat varicose veins by sealing them with an adhesive, and differs from procedures that use drugs, laser, radio waves or cuts in the skin to close or remove veins.
For its third quarter fiscal year 2015, MDT recently reported revenue of $4.32 billion, and non-GAAP net income of $1.005 billion, or $1.01 per diluted share. For the fourth quarter fiscal year 2015, MDT expects constant currency revenue growth in the range of 4% to 6% on a combined pro forma basis.
MDT is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
More about Medtronic plc (MDT) at www.medtronic.com
**
Shares of Knowles Corporation (KN) climbed $1.31 (or +7.18%) to $19.55 on Friday's trading session, after brokerage firm Robert W. Baird upgraded the company's stock from Neutral to Outperform and raised its price target from $20.00 to $23.00 per share
KN is a market leader and global supplier of advanced micro-acoustic solutions and specialty components serving the mobile communications, consumer electronics, medical technology, military, aerospace and industrial markets.
More about Knowles Corporation (KN) at www.knowles.com.
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Santa Maria, CA ( www.santamaria.crwe-pr.com ) into the CRWE Network.
Located in the center of California's Central Coast in Santa Barbara County, the city of Santa Maria lies 270 miles south of San Francisco and 170 miles north of Los Angeles. It is notable for its wine industry and Santa Maria-style barbecue.
The City of Santa Maria had an estimated population in 2013 (U.S. Census Bureau) of 102,216, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s division CRWE Tube ( www.crwetube.com ) is expected to be integrated in all the CRWE Network
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
The company announced five-year results from the pivotal SANTE (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy) trial, the largest clinical study of deep brain stimulation (DBS) therapy for epilepsy in adults with treatment-resistant (refractory) epilepsy characterized by partial-onset seizures.
MDT said that its DBS Therapy for Epilepsy was associated with a sustained and statistically significant reduction in seizure frequency from baseline that continued to improve over time, and the results also show sustained safety, intervals of seizure freedom, improvements in quality of life and reduction in seizure severity
MDT's DBS Therapy for Epilepsy uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver electrical stimulation to a target in the brain called the anterior nucleus of the thalamus, which has strong connections to other parts of the brain where seizures begin.
Furthermore, the U.S. Food and Drug Administration (FDA) has approved the VenaSeal closure system (VenaSeal system) to permanently treat varicose veins of the legs by sealing the affected superficial veins using an adhesive agent. The device is manufactured by Covidien LLC, whose acquisition MDT completed last month for $49.9 billion.
MDT's VenaSeal system permanently treat varicose veins by sealing them with an adhesive, and differs from procedures that use drugs, laser, radio waves or cuts in the skin to close or remove veins.
For its third quarter fiscal year 2015, MDT recently reported revenue of $4.32 billion, and non-GAAP net income of $1.005 billion, or $1.01 per diluted share. For the fourth quarter fiscal year 2015, MDT expects constant currency revenue growth in the range of 4% to 6% on a combined pro forma basis.
MDT is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
More about Medtronic plc (MDT) at www.medtronic.com
**
Shares of Knowles Corporation (KN) climbed $1.31 (or +7.18%) to $19.55 on Friday's trading session, after brokerage firm Robert W. Baird upgraded the company's stock from Neutral to Outperform and raised its price target from $20.00 to $23.00 per share
KN is a market leader and global supplier of advanced micro-acoustic solutions and specialty components serving the mobile communications, consumer electronics, medical technology, military, aerospace and industrial markets.
More about Knowles Corporation (KN) at www.knowles.com.
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Santa Maria, CA ( www.santamaria.crwe-pr.com ) into the CRWE Network.
Located in the center of California's Central Coast in Santa Barbara County, the city of Santa Maria lies 270 miles south of San Francisco and 170 miles north of Los Angeles. It is notable for its wine industry and Santa Maria-style barbecue.
The City of Santa Maria had an estimated population in 2013 (U.S. Census Bureau) of 102,216, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s division CRWE Tube ( www.crwetube.com ) is expected to be integrated in all the CRWE Network
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)